Biochemistry & Physiology: Open Access
Open Access

Biography

Dr. Ahmad has extensive research experience in the field of Immunology, Biochemistry and cell signaling. The broad aim of his research is examination of cellular and molecular mechanisms differentially regulating the signaling of T cell subset signaling, function and survival. The aim of in depth examination of these signaling pathways is the development of strategies to selectively manipulate specific subsets to enhance the efficacy of immune therapies. Phosphoinositide 3-kinase (PI3K)-Akt signaling is important for the differentiation, proliferation, and survival of a variety of cells, including immune cells. Dr. Shamim Ahmad evaluated the anti-tumor efficacy of combinational immunotherapy based on model vaccine and PI3K isoform specific inhibitor. He demonstrates that this treatment leads to a profound inhibition of tumor growth. He showed that the potent therapeutic efficacy of treatment is mediated by i) enhancing number of the effector T cells infiltrating into the tumor that is facilitated and ii) the decrease Tregs. Thus, he provides a promising and translatable strategy that can enhance the overall efficacy of cancer immunotherapy.

Research Interest

His research is focused on development of combinational cancer immunotherapies, immune corrective strategies and investigation of cellular and molecular mechanisms involved in tumor-mediated immune suppression, and development of strategies to overcome that suppression.

Certificate